Citations

Clear

24 citation(s) found for "Seow, C".

Is combined gluteus maximus and tensor fascia latae transfer for irreparable hip abductor tears superior to gluteus maximus transfer alone? A systematic review and meta-analysis
Clark, Sean C. , Lee, Seungjun , Hevesi, Mario, Sierra, Rafael J. , Sierra, Rafael J , Thomas, Terence L. , Hevesi, Mario , Goh, Graham Seow-Hng

Mayo Clinic

HIP International | April 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/11207000261425168 | PMID 41934207 Get It

Background: Chronic hip abductor insufficiency remains a challenging problem to treat and can result in significant disability in some patients. Tendon transfers involving the gluteus maximus (GM) or combined GM with tensor fascia latae (GM+TFL) are common options for surgical reconstruction. The purpose of this systematic review was to compare clinical outcomes, complications, and revisions rates of patients who underwent GM transfer or GM+TFL transfer for irreparable hip abductor tears. Methods: PubMed (MEDLINE), Scopus (EMBASE, MEDLINE, COMPENDEX), and Cochrane databases were used to conduct a systematic review of articles from inception to February 2025. A total of 18 studies were included (11 GM transfer, 7 GM+TFL transfer). Demographics, hip setting (native hip, primary total hip arthroplasty [THA], revision THA), patient-reported outcome measures, presence of Trendelenburg gait, abduction strength, complication rates, and revision rates were analysed. Results: A total of 207 patients (208 hips) underwent GM transfer, while 55 patients (55 hips) underwent GM+TFL transfer. Meta-analyses demonstrated that both techniques yielded significant preoperative to postoperative improvements in modified Harris Hip Scores/Harris Hip Scores and Visual Analogue Scale pain scores ( p < 0.001). In total, 33.9% of patients who underwent GM transfer had a persistent Trendelenburg gait postoperatively, compared to 48.1% of those who underwent GM+TFL transfer. The complication rate was 16.8% (23/137) for patients who underwent GM transfer and 2.7% (1/37) for those who underwent GM+TFL transfer; while revision rates were 5.9% (9/152) and 3.6% (2/55), respectively. Conclusions: Both GM and GM+TFL transfers yielded comparable outcomes in patients with chronic hip abductor insufficiency not amendable to primary repair. The complication rate was substantially higher in patients who underwent GM transfer, whereas revision rates were comparably low for both techniques. In particular, a sizeable proportion of patients continued to exhibit a persistent Trendelenburg gait postoperatively following both surgical techniques, highlighting the complexity of this pathology. PROSPERO registration number: CRD420251002466
DOP041 Pregnancy and Infant Outcomes After In Utero Exposure to JAK Inhibitors in Inflammatory Bowel Disease: A Global Multicenter Cohort Study
Julsgaard, M, Baunwall, S M, Seow, C, Duricova, D, Kane, S, Zacharias, N, Cremer, A, Kok, K, Kagramanova, A V, Pipek, Barbora , Candido, K, Filip, R, Kiudelis, Vytautas , Pugliese, D, Silva, G Oliveira Santana, Savarino, E V, Smolović, Brigita , Wei, S C, Mahadevan, Uma, Julsgaard, Mette , Seow, Cynthia H., Leong, Rupert W. , Kok, K, Kagramanova, A , Candido, Kristen, Cooney, Rachel , Filip, R, Konečný, M , Paramsothy, Sudarshan , Vieujean, Sophie

Mayo Clinic

Journal of Crohn’s and Colitis | January 21, 2026 | Volume: 20 | Issue: Supplement_1 | Pages: No page available

10.1093/ecco-jcc/jjaf231.078 Get It

Abstract Background JAK inhibitors (JAKi) are small molecules that cross the placenta from early pregnancy.1 Evidence on the safety of in utero JAKi exposure remains limited, particularly regarding pregnancy outcomes, infant infections, vaccine responses, and early development.2, 3 Methods We conducted a multicenter retrospective study within the ECCO CONFER network, including pregnant women with inflammatory bowel disease (IBD) exposed to tofacitinib (TOFA), upadacitinib (UPA), or filgotinib (FILGO). Data were collected from 22 centers across 16 countries and included maternal characteristics, disease activity, medication patterns, and pregnancy and infant outcomes. Results Among 55 JAKi exposed pregnancies, 21 (38.2%) were unplanned and 30 (54.6%) had active disease. Nine women (16.4%) initiated JAKi during pregnancy. Overall, 38 (69.1%) received TOFA, 15 (27.3%) UPA, and 2 (3.6%) FILGO; 39 (70.9%) continued treatment throughout pregnancy. JAKi discontinuation in 1st-2nd trimester led to disease activity in 9/16 cases (56.3%). Maternal complication risk was low: no DVT or (pre) eclampsia occurred; three cases of premature rupture of membranes (GA 34–37) and four required hospitalizations due to infection or other complications. A total of 10 abortions occurred - five spontaneous (9.1%) and five induced (9.1%), including three due to concern about JAKi exposure. Among 45 live births, two infants (3.6%) were preterm, four (7.3%) small for gestational age, and two (3.6%) had Apgar &lt;7 at 5 minutes. No congenital abnormalities were reported. Infant follow-up findings are summarized in Table 1. One-third of breastfeeding women continued JAKi postpartum. A high adherence rate to the national immunization schedule was seen. Eight (19.5%) received the live BCG-vaccine within the first 30 days of life. No adverse events followed live or inactivated vaccines, and no malignancies were observed. Conclusion In this global cohort of JAKi-exposed pregnancies in women with IBD, maternal complication rates were low, and no increased risk of adverse outcomes among live births was identified. While disease activity was common, particularly following discontinuation of JAKi, infant outcomes - including development, infection risk, and vaccine response - were reassuring. These findings provide important preliminary safety data to inform decision-making regarding JAKi use in pregnancy, though prospective studies are needed to confirm long-term safety. References: 1.Fein KC, Arral ML, Kim JS, et al. Placental drug transport and fetal exposure during pregnancy is determined by drug molecular size, chemistry, and conformation. J Control Release 2023;361:29–39. 2.Torres J, Chaparro M, Julsgaard M, et al. European Crohn’s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation. J Crohns Colitis 2023;17:1–27. 3.Mahadevan U, Seow CH, Barnes EL, et al. Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease. J Crohns Colitis 2025;epub ahead of print. Conflict of interest: Julsgaard, Mette: No conflict of interest Baunwall, Simon MD: No conflict of interest Seow, Cynthia: No conflict of interest Duricova, Dana: No conflict of interest Kane, Sunanda: No conflict of interest Zacharias, Neha: No conflict of interest Leong, Rupert: No conflict of interest Cremer, Anneline: No conflict of interest Kok, Klaartje: No conflict of interest Kagramanova, Anna Valeryevna: No conflict of interest Pipek, Barbora: No conflict of interest Candido, Kristina: No conflict of interest Cooney, Rachel: No conflict of interest Filip, Rafal: No conflict of interest Kiudelis, Vytautas: No conflict of interest Konečný, Michal: No conflict of interest Paramsothy, Sudarshan: No conflict of interest Pugliese, Daniela: No conflict of interest Oliveira Santana Silva, Genoile: Honoraria - Abbvie, Johnson & Johnson, Ferring, Takeda. Research - Abivax, Takeda, Johnson & Johnson, Roche, Sanofi, Polpharma. Advisory board - Abbvie, Johnson & Johnson, MSD. Savarino, Edoardo Vincenzo: No conflict of interest Smolovic, Brigita: No conflict of interest Vieujean, Sophie: No conflict of interest Wei, Shu Chen: No conflict of interest Mahadevan-Velayos, Uma: No conflict of interest
Fibroblasts Exposed to Serum Collected After Long-Term Calorie Restriction Have Lower Mitochondrial Respiration
Seow, Lek Wei , Dozier, Stephen , Sun, Nina, Bergstrom, Jaclyn , LeBrasseur, Nathan K. , Molina, Anthony

Mayo Clinic

Innovation in Aging | January 3, 2026 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/geroni/igaf122.2543 Get It

Abstract Multiple lines of evidence suggest that calorie restriction may slow biological processes related to aging and extend lifespan. To determine whether calorie restriction affects mitochondrial function, we treated fibroblasts from adult donors with serum samples obtained from participants of the CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) study. The CALERIE study enrolled healthy, non-obese middle-aged (average 38y.o) participants to examine the effects of long-term calorie restriction. We studied the serum samples of 177 participants (calorie restriction CR = 121, ad libitum AL = 56) who had specimens available at two timepoints (12 and 24 months). We assessed the basal and maximal mitochondrial respiration of fibroblasts treated with dilute serum for 24 hours. Our results show that the baseline basal and maximal mitochondrial respiration of fibroblasts is positively correlated with the adiposity of the serum donor (R = 0.112, P = 0.137; R = 0.183, P = 0.015, respectively). Interestingly, treatment of fibroblasts with serum collected after 12 months of calorie restriction causes a decrease in both basal and maximal mitochondrial respiration (P = 0.1854; P = 0.0623, respectively). Fibroblasts treated with serum collected after 24 months of calorie restriction exhibited a further reduction in both basal and maximal mitochondrial respiration (P = 0.0174; P = 0.0092, respectively). These findings suggest that the serum of individuals on long term calorie restriction diet comprises factors that can reduce oxidative phosphorylation. This reduction in bioenergetic capacity may align with the theory that calorie restriction leads to a cellular energy-conserving state, which could have implications for cellular aging and metabolism.
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers
Blechter, Batel , Wang, Xiaoyu , Karsonaki, Christiana, Shi, Jianxin , Shiraishi, Kouya , Choi, Jiyeon , Matsuo, Keitaro , Chen, Tzu‐Yu , Kim, Young Tae , Choudhury, Parichoy Pal , Williams, Jacob , Landi, Maria Teresa , Yin, Zhihua , Zhou, Baosen , Seow, Wei Jie , Song, Lei , Chang, I‐Shou , Chien, Li-Hsin , Wong, Maria Pik , Richardson, Brian Douglas , Li, Shilan , Breeze, Charles E. , Bassig, Bryan A. , Sm, Jason Yy Wong, Chung, Lap Ping, Zhang, Xu‐Chao , Caporaso, Neil E. , Chang, Jiang , Ho, Jcm , Momozawa, Yukihide , Kobayashi, Masashi , Okubo, Kenichi , Honda, Takayuki , Kunitoh, Hideo , Watanabe, Shun-ichi, Hamamoto, Ryuji , Goto, Kōichi , Minamiya, Yoshihiro, Wakai, Kenji , Murakami, Yoshinori , Shimizu, Kimihiro , Suzuki, Hiroyuki , Ohtaki, Yoichi , Tanaka, Kazumi , Wu, Tangchun , Wei, Fusheng, Kim, Yeul Hong , Chang, Gee-Chen , Chen, Kuan‐Yu, Chen, Yuh-Min, Park, Jae Yong , Kweon, Sun-Seog, Gao, Yu‐Tang , Schwartz, Ann G. , Gorlov, Ivan , Wu, Xifeng , Yang, Ping , Lam, Stephen , Bojesen, Stig E. , Ji, Bu‐Tian , Wichmann, H. E., Christiani, D.C., Brennan, Paul , McKay, James , Field, John K. , Shete, Sanjay , Marchand, Loı̈c Le, Liu, Geoffrey , Andrew, Angeline S. , Zienolddiny-Narui, Shan, Grankvist, Kjell , Taylor, Fiona, Aldrich, Melinda C. , Jeon, Hyo‐Sung, Hu, Zhibin , Burdett, Laura, Yeager, Meredith, Hutchinson, Amy , Hicks, Belynda , Liu, Jia , Berndt, Sonja I, Wu, Wei , Wang, Junwen , Choi, Jin Eun , Park, Kyong Hwa , Sung, Sook Whan , Tan, Wen , Sihoe, Alan , Choi, Yi Young, Hung, Hsiao-Han , Vermeulen, Roel , Wu, Junjie , Tsai, Fang-Yu , Chan, John K. C., Li, Jihua , Lin, Hsien-Chih, Liu, Jie , Sawada, Norie , Yamaji, Taiki , Wyatt, Kathleen , Qi, T. Y., Li, Xuelian , Ren, Yangwu , Chao, Ann, Zhu, Junjie , Chen, Chih‐Yi , ScD, Chien-Jen Chen, Stevens, Victoria L. , Fraumeni, Joseph F., Lin, Kuang , Walters, Robin G., Chen, Zhengming, Chatterjee, Nilanjan , Gorlova, Olga Y. , Hsiung, Chao A. , Chanock, Stephen J, Rothman, Nathaniel , Kohno, Takashi , Lan, Qing, Kartsonaki, Christiana , Liu, Geoffrey , Field, John K , Matsuo, Keitaro , Wang, Junwen , Bojesen, Stig E , Grankvist, Kjell , Chen, Chih-Yi , Dai, Juncheng , Hung, Rayjean J. , Chen, Kexin , Shu, Xiao-Ou , Choudhury, Parichoy Pal , Lin, Dongxin , Zheng, Wei , Wang, Jiucun , Hu, Wei , Cai, Qiuyin , Hong, Yun‐Chul , Kim, Hee Nam , Wu, Yi-Long Lung Cancer , Richardson, Brian Douglas , Zhang, Tongwu , Wang, Zhaoming , Kim, Jin Hee , Albanes, Demetrius , Shin, Min‐Ho , Chung, Lap-Ping, Yang, Yang , Zheng, Hong , Dai, Hong , Yatabe, Yasushi , Kim, Young‐Chul , Daigo, Yataro , Kamatani, Yoichiro , Kobayashi, Masashi , Hosgood, Howard Dean , WATANABE, Shun-ichi J. , Miyagi, Yohei , Matsumoto, Shingo , Horinouchi, Hidehito , Tsuboi, Masahiro , Takahashi, Atsushi , Goto, Akiteru , Hara, Megumi , Nishida, Yuichiro , Takeuchi, Kenji , Matsuda, Koichi , Murakami, Yoshinori, Suzuki, Hiroyuki , Saito, Motonobu , Machiela, Mitchell J. , Oh, In‐Jae , Lee, Victor , Su, Wu‐Chou , Seow, Adeline , Kweon, Sun-Seog , Liu, Jianjun , Houlston, Richard S. , Tardón, Adonina , Chen, Chu, Johansson, Mattias , Risch, Angela , Bickeböller, Heike , Rennert, Gad , Arnold, Susanne M. , Davies, Michael P.A. , Kiemeney, Lambertus A. , Cox, Angela , Yuan, Jian-Min , Lazarus, Philip J. , Schabath, Matthew B. , Jiang, Shih Sheng , Chen, Chung–Hsing , Hsiao, Chin‐Fu , Yeager, Meredith , Liu, Jia , Berndt, Sonja I. , Li, Yuqing , Kang, Chang Hyun , Wang, Wen‐Chang , Xu, Jun, Guan, Peng , Yu, Chong‐Jen , Yang, Gong , Park, In Kyu , Cheng, Iona C. , Song, Bao, Wyatt, Kathleen , Ma, Hongxia , Zhu, Meng , Wang, Yifan , Qi, Tianchen, Iwasaki, Motoki , Wu, Guoping , Yang, Pan‐Chyr , Walters, Robin G. , Chatterjee, Nilanjan , Amos, Christopher I. , Shen, Hongbing , Rothman, Nathaniel , Lan, Qing , Zhang, Haoyu

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 18, 2025 | Volume: 118 | Issue: 2 | Pages: 231-249

10.1093/jnci/djaf272 | PMID 41032288 Get It

Abstract Background Lung adenocarcinoma in never-smokers is a major public health burden, especially among East Asian women. Polygenic risk scores (PRSs) are promising for risk stratification but are primarily developed in European-ancestry populations. We aimed to develop and validate single- and multi-ancestry PRSs for East Asian never-smokers to improve lung adenocarcinoma risk prediction. Methods PRSs were developed using genome-wide association study summary statistics from East Asian (8002 cases; 20 782 controls) and European (2058 cases; 5575 controls) populations. Single-ancestry models included a PRS with 25 single nucleotide variants (PRS-25), PRS clumping and thresholding (CT), and LDpred2; multi-ancestry models included LDpred2 plus European PRS-128, PRS-CSx, and clumping and thresholding, super learning, empirical Bayes (CT-SLEB). Performance was evaluated in independent East Asian data from the Female Lung Cancer Consortium and externally validated in the Nanjing Lung Cancer Cohort. We assessed predictive accuracy via area under the curve operating procedure (AUC), with 10-year and (ages 30-80 years) absolute risks estimates. Results The best multi-ancestry PRS, using East Asian and European data via CT-SLEB, outperformed the best East Asian-only (LDpred2; AUC = 0.629, 95% confidence interval [CI] = 0.618 to 0.641), achieving an AUC of 0.640 (95% CI = 0.629 to 0.653) and odds ratio of 1.71 (95% CI = 1.61 to 1.82) per standard deviation increase. Nanjing Lung Cancer Cohort validation confirmed robust performance (AUC = 0.649, 95% CI = 0.623 to 0.676). The top 20% PRS group had a 3.92-fold higher lung adenocarcinoma risk than the bottom 20%. Further, the top 5% PRS group reached a 6.69% lifetime absolute risk. Notably, this group reached the average population 10-year lung adenocarcinoma risk at age 50 years (0.42%) by age 41 years, 9 years earlier. Conclusions Multi-ancestry PRS approaches enhance lung adenocarcinoma risk stratification in East Asian never-smokers, with consistent external validation, suggesting future clinical utility.
Global consensus statement on the management of pregnancy in inflammatory bowel disease
Mahadevan, Uma , Seow, Cynthia H. , Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda, Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Duricova, Dana, Dubinsky, Marla, Long, Millie D. , Huang, Vivian , Julsgaard, Mette , Barnes, Edward L. , Chaparro, María , Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Gearry, Richard B.

Mayo Clinic

Gut | September 9, 2025 | Volume: 75 | Issue: 2 | Pages: 208-251

10.1136/gutjnl-2025-336402 | PMID 40876906 Get It

Background & aims Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 Consensus statements. Conclusions Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Barnes, Edward L. , Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda, Torres, Joana , Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Ďuricová, Dana , Dubinsky, Marla, Long, Millie D. , IBD, Global Consensus Group for Pregnancy and, Maria, Abreu, Ali, Azzam Nahla, Wafaa, Badre, Rupa, Banerjee, Sally, Bell, Susan, Connor, Iris, D, Marc, Ferrante, Emily, Feneberg, Ryota, Hokari, Vivian, Huang, Patricio, Ibanez, Juliao, Fabián, Leolin, Katsidzira, Alicia, Sambuelli, Christian, Selinger, Astrid, Williams, Jessica, L Thomson, Nicole, A. Capela, Wenli, Chen, Natalie, Hayden, Chun, Lin, Brosbol, Ravnborg Anne, Njeri, Mwaura-Ruhio Treza, Lindsay, Rous, Chaparro, María , Flanagan, Emma , Friedman, Sonia , Julsgaard, Mette , Ng, Siew C , Torres, Joana , Yamamoto-Furusho, Jesus , Barnes, Edward L , Friedman, Sonia , Ng, Siew C. , Robinson, Christopher James , Gearry, Richard B. , IBD, Global Consensus Group for Pregnancy and, Ali, Azzam Nahla, Marc, Ferrante, Emily, Finlayson, Ryota, Hokari, Vivian, Huang, Patricio, Ibanez, Wei, Shu‐Chen , Zaltman, Cyrla , Wenli, Chen, Lindsay, Rous

Mayo Clinic

Journal of Crohn’s and Colitis | September 7, 2025 | Volume: 19 | Issue: 8 | Pages: No page available

10.1093/ecco-jcc/jjaf129 | PMID 40914850 Get It

Abstract Background & Aims Pregnancy can be a complex and risk-filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND (Research and Development) process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements. Conclusions Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Real‐World Outcomes of Transplant Ineligible Older Adults With Multiple Myeloma Treated With Novel Regimens: A Population‐Based Retrospective Cohort Study
Abdallah, Nadine , Mian, Hira , Seow, Hsien , Pond, Gregory P., Gayowsky, Anastasia , Fonseca, Rafael, Cook, Gordon , Kumar, Shaji , Pond, Gregory R. , Kumar, Shaji K , Chakraborty, Rajshekhar , Pond, Gregory Russell , Mian, Hira , Cook, Gordon , Visram, Alissa , Costa, Luciano J. , Wildes, Tanya M. , Fonseca, Rafael, Pawlyn, Charlotte , Chakraborty, Rajshekhar

Mayo Clinic

American Journal of Hematology | August 29, 2025 | Volume: 100 | Issue: 11 | Pages: 2144-2149

10.1002/ajh.70042 | PMID 40879697 Get It

Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Barnes, Edward L., Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda V. , Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Duricova, Dana, Dubinsky, Marla, Long, Millie, IBD, the Global Consensus Group for Pregnancy and, Huang, Vivian , Julsgaard, Mette , Barnes, Edward L., Chaparro, María , Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Gearry, Richard B. , IBD, the Global Consensus Group for Pregnancy and

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 28, 2025 | Volume: 62 | Issue: 11-12 | Pages: 1125-1180

10.1111/apt.70290 | PMID 40874657 Get It

ABSTRACT Background & Aims Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High‐quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements. Conclusions Overall, the goal of the group was to provide data‐driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda V. , Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Ďuricová, Dana , Dubinsky, Marla C. , Long, Millie, IBD, the Global Consensus Group for Pregnancy and, Huang, Vivian , Julsgaard, Mette , Barnes, Edward L. , Chaparro, María , Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Gearry, Richard B. , IBD, the Global Consensus Group for Pregnancy and

Mayo Clinic

American Journal of Gastroenterology | August 27, 2025 | Volume: 121 | Issue: 1 | Pages: 31-79

10.14309/ajg.0000000000003651 | PMID 40862489 Get It

Introduction: Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods: The GRADE process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results: The topics were divided into 10 categories with 34 GRADE recommendations and 35 Consensus statements. Discussion: Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Chaparro, María, Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda V. , Watermeyer, Gillian , Fisher, Susan G. , Anderson, Phil, Duricova, Dana, Dubinsky, Marla C. , Long, Millie, IBD, Global Consensus Group for Pregnancy and, Barnes, Edward L, Chaparro, María, Kane, Sunanda, Ng, Siew, Fisher, Susan, Dubinsky, Marla, Long, Millie, Huang, Vivian , Julsgaard, Mette , Barnes, Edward L. , Chaparro, María, Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Fisher, Susan, Gearry, Richard B. , IBD, Global Consensus Group for Pregnancy and, Barnes, Edward L, Chaparro, María, Ng, Siew, Dubinsky, Marla, Long, Millie

Mayo Clinic

Inflammatory Bowel Diseases | July 15, 2025 | Volume: 31 | Issue: 10 | Pages: 2615-2664

10.1093/ibd/izaf171 | PMID 40874613 Get It

Abstract Background & Aims Pregnancy can be a complex and risk-filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND (Research and Development) process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements. Conclusions Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.